THP-1 Cell Culture, Differentiation, and Applications

THP-1 is a human monocytic cell line originally derived from the blood of an infant boy with acute monocytic leukemia, and it has become one of the most widely used in vitro models for studying macrophage biology, innate immunity, and inflammation. Its popularity stems from a practical advantage: these cells grow in suspension as monocyte-like precursors, then can be chemically coaxed into adherent macrophage-like cells that mimic many behaviors of the macrophages found in living tissue. That two-step flexibility makes THP-1 cells useful across a surprisingly broad range of research, from tuberculosis drug screening to cosmetic safety testing to cancer immunology.

Where THP-1 Cells Come From

The cell line was established and characterized in 1980 by Tsuchiya and colleagues. The original paper confirmed that THP-1 cells carry hallmarks of genuine monocytes: they have receptors for antibody fragments (Fc receptors) and complement components, they produce lysozyme, they can swallow latex particles and opsonized red blood cells, and they possess a specific esterase activity pattern that marks them as monocytic rather than granulocytic.¹ Because THP-1 cells are a continuous cell line, they can be expanded indefinitely in culture, unlike primary monocytes harvested from donor blood, which are limited in number, vary from donor to donor, and cannot be maintained long-term.

Compared to other human myeloid cell lines such as U937, HL-60, and KG-1, differentiated THP-1 cells behave more like native monocyte-derived macrophages in functional assays.² That closer resemblance is a major reason THP-1 has overtaken its competitors in published research. Still, the cells are leukemic in origin, and that distinction matters in ways discussed later.

Growing and Maintaining THP-1 Cells

Undifferentiated THP-1 cells grow in suspension in standard culture medium, typically RPMI-1640 supplemented with fetal bovine serum and a reducing agent like beta-mercaptoethanol. They divide with a doubling time of roughly 35 to 50 hours, depending on culture conditions. Keeping the density within a comfortable range is important; overcrowded flasks lead to nutrient depletion and altered cell behavior that can affect downstream experiments.

One practical concern for labs scaling up is the cost and variability of serum. Recent work has explored adapting THP-1 cells to chemically defined serum-free media, with the goal of making large-scale production more economical and reproducible. Researchers have demonstrated that THP-1 cells can be gradually adapted to serum-free conditions and even grown in stirred-tank bioreactors, opening a path toward biopharmaceutical applications.³ For most academic labs, though, the standard serum-supplemented approach remains the norm.

Differentiation Into Macrophages With PMA

The defining feature of THP-1 culture is the ability to trigger differentiation from monocyte-like suspension cells into adherent, macrophage-like cells. The most common stimulus is phorbol 12-myristate 13-acetate, widely known as PMA. When you add PMA to THP-1 cells, they stop dividing, flatten out, stick to the culture surface, and begin expressing macrophage surface markers like CD11b. Functionally, they gain the ability to phagocytose particles and to produce inflammatory cytokines in response to bacterial products.

PMA works by activating protein kinase C (PKC), a family of signaling enzymes that sit at a crossroads of cellular decision-making. Activation of specific PKC isoforms, particularly PKC-delta, drives the downstream signaling that commits THP-1 cells toward a macrophage fate. Research has shown, for instance, that compounds like curcuminoids can block PMA-induced differentiation markers by inhibiting PKC-delta and the reactive oxygen species it helps generate, confirming that this pathway is central to the process.⁴

Why the Resting Step Matters

A pitfall that has tripped up many labs is treating PMA-differentiated THP-1 cells as if they are ready to use the moment they become adherent. Cells harvested immediately after continuous PMA exposure are in a heightened, somewhat artificial state. They tend to display elevated baseline levels of inflammatory proteins, which can bias the results of any experiment looking at immune activation.

A resting period of several days in PMA-free medium after the initial differentiation pulse dramatically improves how closely THP-1-derived macrophages resemble primary monocyte-derived macrophages. Research comparing cells given PMA for 48 hours straight against cells given PMA followed by rest found that the rested cells had lower baseline levels of pro-inflammatory proteins like pro-IL-1β, making them a cleaner starting point for inflammasome studies.⁵ A separate study found that five days of rest after PMA treatment produced cells with increased organelle numbers, altered surface markers, and resistance to programmed cell death in a pattern closely matching primary macrophages.⁶ For anyone setting up THP-1 experiments for the first time, building in this resting step is probably the single most impactful protocol adjustment you can make.

Vitamin D3 as an Alternative Differentiating Agent

PMA is not the only way to push THP-1 cells toward a macrophage phenotype. The active form of vitamin D, 1,25-dihydroxyvitamin D3, also induces differentiation, but it produces a distinctly different type of cell. Compared to PMA-treated cells, vitamin D3-differentiated THP-1 cells are less fully committed to the macrophage state: they show weaker adherence, retain some ability to proliferate, and phagocytose particles less aggressively. They also do not produce prostaglandin E2, whereas PMA-differentiated cells do, and they release less TNF-alpha in response to bacterial lipopolysaccharide.⁷

These differences stem from the distinct signaling pathways each agent activates. PMA strongly triggers PKC-delta and PKC-alpha, while vitamin D3 preferentially upregulates PKC-beta.⁷ The practical takeaway is that the choice of differentiating agent is not just a matter of convenience; it shapes the kind of macrophage-like cell you end up with, and that matters for how you interpret your results.

Polarizing THP-1 Macrophages Into M1 and M2 States

Real macrophages in the body do not exist in a single generic state. They adopt specialized functional profiles depending on the signals in their environment. At one end, classically activated (M1) macrophages are pro-inflammatory, geared toward killing pathogens and secreting cytokines like TNF-alpha and IL-6. At the other end, alternatively activated (M2) macrophages lean toward tissue repair and immune suppression. THP-1-derived macrophages can be pushed toward both poles.

For M1 polarization, the standard approach is treating PMA-differentiated THP-1 cells with interferon-gamma and lipopolysaccharide. This combination boosts expression of pro-inflammatory markers including TNF-alpha, IL-1β, IL-6, CXCL10, CD80, and HLA-DR.⁸ For M2 polarization, cytokines such as IL-4 or IL-10 are added instead. Standardized protocols for generating these distinct phenotypes have been developed to improve reproducibility across labs.⁹ Validated methods for cancer research specifically have also been published.¹⁰

One subtlety worth noting: the published literature skews heavily toward M1-like THP-1 macrophages, partly because the standard PMA differentiation protocol already pushes cells in a pro-inflammatory direction.⁹ Generating a convincing M2 phenotype requires more careful optimization, and the resting step discussed earlier can help by bringing the baseline inflammatory state down before you try to steer cells in an anti-inflammatory direction.

Studying Phagocytosis and Antibody Function

Because macrophages are professional eaters, one of the most common applications of THP-1 cells is measuring phagocytosis. Undifferentiated THP-1 cells already express a range of Fc receptors, which makes them useful in high-throughput assays measuring how well antibodies trigger the uptake of pathogens. A flow-cytometry-based phagocytosis assay using THP-1 cells has been adapted to screen antibodies against influenza, HIV, and dengue viruses.¹¹ This kind of functional readout is valuable in vaccine development, where knowing that a vaccine elicits antibodies is less informative than knowing those antibodies can actually direct immune cells to destroy the target.

As THP-1 cells differentiate, their phagocytic capacity changes in interesting ways. Over a week of PMA-driven differentiation, general phagocytic activity roughly doubles, with uptake through Fc receptors dominating at early time points. By day seven, though, mannose receptor-mediated uptake increases sharply, a shift that resembles the M2 macrophage phenotype.¹² This plasticity is a reminder that the length of your differentiation protocol can affect which type of phagocytosis your cells favor.

Inflammasome and Cytokine Research

THP-1 cells are a workhorse model for studying the NLRP3 inflammasome, a molecular complex that triggers the release of the potent inflammatory cytokine IL-1β. When exposed to bacterial endotoxin, THP-1 monocytes and their macrophage derivatives activate the inflammasome, which in turn activates the enzyme caspase-1, which cleaves pro-IL-1β into its mature, secreted form. This pathway is a major therapeutic target in conditions ranging from gout to cardiovascular disease.

Drug discovery researchers use THP-1 cells to screen compounds that might block this cascade. For example, the investigational compound luxeptinib has been shown to disable the NLRP3 inflammasome’s ability to activate caspase-1 in THP-1 cells, blocking IL-1β release without preventing the inflammasome from assembling in the first place.¹³ On the other side of the coin, vitamin D metabolites have been found to enhance IL-1β secretion from THP-1 cells in a caspase-1-dependent manner.¹⁴ The ability to study both activation and inhibition of the same pathway in the same cell line, with reproducible results, is a large part of why THP-1 cells dominate this field.

Modeling Tuberculosis and Intracellular Infections

Tuberculosis research has a particular affinity for THP-1 cells. The bacterium that causes TB, Mycobacterium tuberculosis, naturally infects and survives inside alveolar macrophages, so any lab model needs a macrophage it can infect reliably. PMA-differentiated THP-1 cells serve as a widely used platform for studying this interaction and for screening anti-TB drugs.¹⁵

Importantly, THP-1 macrophages reproduce key features of primary macrophage responses to mycobacterial infection. Attenuated TB strains and BCG strongly induce apoptosis in THP-1 cells through a mechanism that requires TNF, mirroring what happens in human alveolar macrophages, and this programmed cell death is associated with reduced bacterial survival.¹⁶ High-content imaging techniques have been developed that use fluorescent markers to distinguish live from dead bacteria inside THP-1 macrophages, enabling automated screening of drug candidates.¹⁷

Safety Testing and Toxicology

Beyond basic research, THP-1 cells have carved out a role in regulatory safety testing. One prominent example is skin sensitization testing. Regulatory bodies including the OECD now recommend in vitro methods as animal-free alternatives for assessing whether chemicals in cosmetics and topical drugs can cause allergic skin reactions. The human cell line activation test (h-CLAT) uses THP-1 cells as biosensors: when exposed to a skin sensitizer, THP-1 cells upregulate certain surface markers, and the degree of upregulation predicts sensitization potential. Newer versions of this assay use PCR-based readouts to make the process faster and cheaper.¹⁸

THP-1 macrophages also feature in nanotoxicology studies assessing the safety of nanoparticles and microplastics. When PMA-differentiated THP-1 macrophages were exposed to polystyrene nanoplastics in the sub-450 nanometer range, researchers observed decreased viability, oxidative stress, mitochondrial damage, and DNA injury at higher concentrations.¹⁹ Interestingly, when similar polystyrene nanoparticles were tested across three different immune cell lines, undifferentiated THP-1 monocytes showed the highest particle uptake yet no measurable adverse effects, suggesting that the differentiation state of the cell changes its vulnerability.²⁰

Co-Culture Models That Combine THP-1 With Other Cell Types

In the body, macrophages never work alone. They sit alongside epithelial cells, endothelial cells, fibroblasts, and other immune cells, and the crosstalk between these populations determines the tissue response. Researchers have developed co-culture systems that pair THP-1-derived macrophages with other cell lines to capture some of this complexity.

A lung-mimicking model co-cultures THP-1 macrophages with A549 alveolar epithelial cells, grown either submerged or at an air-liquid interface, to study the toxicity of inhaled particulate matter like PM 2.5.²¹ A gut-mimicking model pairs THP-1 macrophages with Caco-2 intestinal epithelial cells on opposite sides of a permeable membrane. In its resting state, the co-culture maintains an intact intestinal barrier with low cytokine output. When the researchers stimulated the system with inflammatory signals, they observed a temporary breach in barrier integrity alongside a burst of pro-inflammatory cytokines, reproducing hallmarks of intestinal inflammation in a dish.²² These composite systems are valuable because they let you test how a stimulus affects the tissue as a unit, not just one isolated cell type.

How Faithfully Do THP-1 Cells Represent Real Macrophages

This is the question that deserves the most honest answer, because the gap between THP-1-derived macrophages and genuine human macrophages is real. When researchers compared gene expression profiles across the entire genome, they found that while PMA-treated THP-1 cells do switch on some of the same genes that primary macrophages express, the overall correlation was not particularly high. Some genes even moved in opposite directions: IL-1β, for example, was regulated differently in THP-1 macrophages than in real macrophages.²³ The authors of that study concluded that while THP-1 cells share morphological and some functional features with macrophages, researchers should be cautious about assuming the two are interchangeable at the molecular level.

This does not invalidate THP-1-based experiments, but it means results need to be interpreted with appropriate care and, ideally, confirmed in primary cells or in vivo models before drawing broad biological conclusions. Think of THP-1 cells as a powerful first-pass screening tool: they offer reproducibility, scalability, and convenience that primary cells cannot match, but they are a simplification of a more complex biological reality.

Genetic Engineering of THP-1 Cells

One area where THP-1 cells have historically been frustrating is genetic manipulation. As suspension cells with relatively low transfection efficiency, they resist the standard lipid-based delivery methods that work well in adherent cell lines. CRISPR-based gene editing in THP-1 cells typically requires lentiviral delivery to achieve stable and efficient gene disruption. A recently published protocol demonstrated this approach by knocking out the GSDMD gene, which encodes a key protein in the inflammatory cell-death pathway called pyroptosis.²⁴ Lentiviral transduction integrates the CRISPR components into the cell’s genome, ensuring that the knockout is stable through subsequent divisions, and this makes it possible to generate clonal knockout lines for detailed mechanistic studies.

Microfluidics and Mechanical Stress

Monocytes in the bloodstream are constantly subjected to fluid shear stress as blood flows past vessel walls. Static culture in a dish misses this dimension entirely. Microfluidic devices address the gap by flowing culture medium over THP-1 cells at controlled velocities, mimicking the forces cells experience in circulation. When THP-1 cells were exposed to shear stress at 15 pascals, they ramped up expression of the adhesion molecule ICAM-1 and released more IL-8, an inflammatory signaling molecule. Paradoxically, despite these pro-inflammatory changes, their actual adhesion to endothelial cells decreased with longer exposure times.²⁵ Findings like these highlight how static culture conditions can miss physiologically important behaviors, and they make a case for incorporating flow-based systems into THP-1 experimental designs, especially for studies related to cardiovascular inflammation.

Modeling Tumor-Associated Macrophages

In cancer research, macrophages that infiltrate tumors often get co-opted by the tumor to promote growth and spread rather than fight it. These tumor-associated macrophages (TAMs) are a major therapeutic target, but studying them requires a system where you can control the signals that turn a normal macrophage into a tumor-friendly one. THP-1 cells fill that role. When THP-1 monocytes were cultured with conditioned media from pancreatic cancer cells, they were attracted toward the tumor signal and polarized into a TAM-like state. These tumor-driven macrophages secreted elevated levels of IL-8 through a signaling pathway involving STAT3, and that IL-8 in turn promoted tumor cell migration.²⁶ This kind of experiment would be logistically difficult with freshly isolated primary macrophages because of the volume of cells needed and the donor-to-donor variability. THP-1 cells provide a consistent, scalable backdrop against which to dissect how tumors hijack the immune system.

Metabolic Shifts During Activation

When monocytes and macrophages encounter an inflammatory signal, they do not just start pumping out cytokines. They rewire their entire metabolic program, shifting how they generate energy and build the molecules they need. THP-1 cells have been used to map these metabolic transitions in detail. During acute inflammation, monocytes ramp up glycolysis and related metabolic branches including the pentose phosphate pathway and hexosamine biosynthesis, aligning their metabolic output with the demands of rapid cell activation.²⁷ Understanding this metabolic reprogramming has practical implications for drug development, since compounds that interfere with these metabolic shifts could dampen pathological inflammation without the broad immunosuppression caused by conventional anti-inflammatory drugs.